La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DIH Holding US a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DIH Holding US..

DIH Holding US (NASDAQ:DHAI) Azioni, Catena delle Opzioni

DIH Holding US

DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US Inc

Scotiabank analyst Himanshu Gupta maintains FirstService (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) with a Sector Perform and lowers the price target from $217.5 to $210.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on FirstService, Lowers Price Target to $210

RBC Capital analyst Jon Arfstrom maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Outperform and lowers the price target from $24 to $22.

RBC Capital Maintains Outperform on First Horizon, Lowers Price Target to $22

Trading Ideas

AVGO

Live On CNBC Bill Baruch Buys More Broadcom

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 21.78% on an annualized basis producing an average annual return of 35.84%. Currently, Murphy USA has a market capitalization of $10.03 billion. 
Buying $1000 In MUSA: If an investor had bought $1000 of MUSA stock 5 years ago, it would be worth $4,652.31 today based on a price of $506.46 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744906632_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

$1000 Invested In Murphy USA 5 Years Ago Would Be Worth This Much Today

RBC Capital analyst Gerard Cassidy maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Outperform and lowers the price target from $50 to $44.

RBC Capital Maintains Outperform on Citizens Financial Group, Lowers Price Target to $44

WIIM

NioCorp shares are trading lower after the company announced the pricing of a $20 million underwritten public offering.

RBC Capital analyst Walter Spracklin maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Sector Perform and lowers the price target from $31 to $30.

RBC Capital Maintains Sector Perform on CSX, Lowers Price Target to $30

Morgan Stanley analyst Brian Nowak maintains Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) with a Underweight and lowers the price target from $35 to $30.

YELP

Morgan Stanley Maintains Underweight on Yelp, Lowers Price Target to $30

Oil is trading higher following new US sanctions on Iranian oil exports.

Morgan Stanley analyst Matthew Cost maintains Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Equal-Weight and lowers the price target from $13 to $10.5.

WBTN

Morgan Stanley Maintains Equal-Weight on Webtoon Entertainment, Lowers Price Target to $10.5

Wells Fargo analyst Aaron Rakers maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Overweight and lowers the price target from $140 to $120.

Wells Fargo Maintains Overweight on Advanced Micro Devices, Lowers Price Target to $120

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $140 to $145.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145

Morgan Stanley analyst Pamela Kaufman maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Overweight and lowers the price target from $40 to $39.

VITL

Morgan Stanley Maintains Overweight on Vital Farms, Lowers Price Target to $39

Adagio Medical Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares are trading higher by 124% to $2.07 during Thursday&#8217;s session after the FDA granted Breakthrough Device Designation for the <a href="https://www.benzinga.com/pressreleases/25/04/b44861813/adagio-medical-holdings-inc-receives-fda-breakthrough-device-designation-for-the-vclastm-cryoablat">vCLAS cryoablation system</a>.
What To Know: Adagio Medical says the system targets drug-resistant, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic structural heart disease. The device is designed to improve VT ablation safety and outcomes.
This designation grants Adagio priority FDA review and enhanced support during the premarket phase. It also reflects promising early data from Adagio's European CRYOCURE-VT study. The device is meanwhile under investigation in the U.S. through the FULCRUM-VT trial, enrolling 206 patients.
Adagio CEO Todd Usen called the designation a major milestone, citing unmet needs in VT treatment. While already approved in Europe, the device remains investigational in the U.S., with plans to pursue premarket approval following study completion.
Read Also: <a href="https://www.benzinga.com/news/25/04/44863298/whats-going-on-with-avis-budget-group-car-stock">What&#8217;s Going On With Avis Budget Group Stock?</a>
<h2 class="wp-block-heading">How To Buy ADGM Stock</h2>
By now you're likely curious about how to participate in the market for Adagio Medical Holdings &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Adagio Medical Holdings, which is trading at $2.23 as of publishing time, $100 would buy you 48.31 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ADGM has a 52-week high of $9.34 and a 52-week low of $0.62.

ADGM

Why Adagio Medical Holdings (ADGM) Stock Is Skyrocketing

Wells Fargo analyst Joseph Quatrochi maintains ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) with a Overweight and lowers the price target from $860 to $840.

ASML

Wells Fargo Maintains Overweight on ASML Holding, Lowers Price Target to $840

Morgan Stanley analyst Matthew Cost maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Overweight and lowers the price target from $32 to $25.

Morgan Stanley Maintains Overweight on Unity Software, Lowers Price Target to $25

BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) has introduced the iShares S&amp;P 500 3% Capped ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOPC#NYSE">TOPC</a>), the first U.S. ETF to limit the weight of individual stocks to 3% in <a href="https://www.benzinga.com/topic/s-p-500">the S&amp;P 500 universe</a>.
The new fund comes at a time when only seven companies now represent over $15 trillion in market value, about the same as the size of the entire U.S. stock market in 2000. 
This increasing concentration has raised alarm about the volatility and unevenness of classic cap-weighted indexes.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/04/44866215/exclusive-defiance-letting-you-go-2x-long-on-quantum-2x-short-on-ai-straight-from-the-ceo">EXCLUSIVE: Why Defiance Is Letting You Go 2X Long On Quantum, And 2X Short On AI, Straight From The CEO</a>
TOPC seeks to mitigate that risk by tracking the S&amp;P 500 3% Capped Index, which redistributes excess weights from mega-cap stocks to the index&#8217;s smaller constituents. The strategy maintains broad market exposure while encouraging more issuer and sector diversification.
The <a href="https://www.businesswire.com/news/home/20250416384950/en/BlackRock-Expands-iShares-Build-ETF-Toolkit-with-Industrys-First-SP-500-3-Capped-Weighted-ETF">fund </a>is part of the iShares Build suite. That&#8217;s BlackRock&#8217;s core building-block ETFs created for retail and institutional investors to gain low-cost, versatile market exposure. After an expense reduction, TOPC has a net expense ratio of 0.09%.
Whereas its exposure is mostly consistent with the legacy S&amp;P 500, TOPC restricts market giants Apple, Microsoft, and Nvidia to being over-exposed, which recently topped 6% weightings in uncapped benchmarks.
The ETF can invest up to 20% of net assets in futures, options, or cash strategies in order to provide exposure during index rebalancing. The core sector exposures are technology and financials, aligned with the rest of the market, but slightly more balanced tilted.
With 468 ETFs <a href="https://stockanalysis.com/etf/provider/blackrock/">according </a>to Stock Analysis, BlackRock&#8217;s new launch highlights its continued effort to provide precision instruments for investors managing a market increasingly dominated by a few tech behemoths.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854262/chipwrecked-nvidias-export-ban-triggers-etf-meltdown-and-one-big-winner">Chipwrecked: Nvidia&#8217;s Export Ban Triggers ETF Meltdown (And One Big Winner)</a></li>
</ul>
Image: Shutterstock

New ETFs

ETFs

iShares Trust iShares S&P 500 3% Capped ETF

TOPC

BlackRock Debuts First 3% Capped S&P 500 ETF To Tame Mega-Cap Dominance

Morgan Stanley analyst Betsy Graseck maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Overweight and lowers the price target from $51 to $50.

Morgan Stanley Maintains Overweight on U.S. Bancorp, Lowers Price Target to $50

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 450 points on Thursday.
The Dow traded down 1.20% to 39,191.93 while the NASDAQ fell 0.09% to 16,293.14. However, the S&amp;P 500 gained 0.30% to 5,291.42.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44836659/top-3-industrials-stocks-that-may-plunge-this-month">Top 3 Industrials Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Energy shares surged by 2.5% on Thursday.
In trading on Thursday, information technology shares fell by 0.9%.
Top Headline
D.R. Horton, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported worse-than-expected second-quarter results and lowered its FY25 guidance.
Sales fell 15% year-over-year (Y/Y) to $7.73 billion, missing the consensus of $8.03 billion. EPS was $2.58, missing the consensus of $2.67. Net sales orders fell 15% Y/Y to 22,437 homes and decreased 17% Y/Y in value to $8.4 billion.
D.R. Horton revised its FY25 revenue guidance to $33.3 billion-$34.8 billion (from $36.0 billion – $37.5 billion) versus the consensus of $36.4 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Baijiayun Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares shot up 60% to $0.3447 after the company announced it formed a partnership with Xinlantian to combine their AI video and large language model technologies with expertise in autism rehabilitation.</li>
<li>Shares of Adagio Medical Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>)got a boost, surging 138% to $2.0792 after the FDA granted Breakthrough Device Designation for the vCLAS cryoablation system.</li>
<li>Channel Therapeutics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>) shares were also up, gaining 52% to $1.9080. Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) and Channel Therapeutics on Thursday signed a definitive merger agreement to combine Ligand's wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.</li>
</ul>
Equities Trading DOWN
<ul>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares dropped 22% to $456.68 after the company reported worse-than-expected first-quarter results and cut its FY25 adjusted EPS guidance below estimates.</li>
<li>Shares of CaliberCos Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) were down 29% to $0.3200 as the company announced the pricing of the public offering units.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) was down, falling 18% to $69.07 after the company announced it bought a stake in Worldpay for $6.6 billion.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $63.47 while gold traded down 1.2% at $3,305.90.
Silver traded down 2.4% to $32.200 on Thursday, while copper fell 1.3% to $4.6255.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.29%, Germany's DAX 40 declined 0.64% and France's CAC 40 dipped 0.76%. Spain's IBEX 35 Index slipped 0.23%, while London's FTSE 100 fell 0.18%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 1.35%, China's Shanghai Composite gaining 0.13%, Hong Kong's Gang Seng index gaining 1.61% and India's BSE Sensex gaining 1.96%.
Economics
<ul>
<li>U.S. housing starts dipped 11.4% month-over-month to an annualized rate of 1.324 million in March.</li>
<li>U.S. initial jobless claims declined by 9,000 from the previous week to 215,000 during the second week of April, versus market estimates of 225,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell 39 points to a reading of -26.4 in April, and down from market estimates of 2.</li>
<li>U.S. building permits climbed by 1.6% to an annualized rate of 1.482 million in March.</li>
<li>U.S. natural-gas stocks rose 16 billion cubic feet in the week ending April 11, compared to market estimates of a 24 billion cubic feet gain.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44862443/intuit-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday">Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CHRO

LGND

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings

RBC Capital analyst Ashish Sabadra maintains Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) with a Outperform and raises the price target from $52 to $62.

RBC Capital Maintains Outperform on Rollins, Raises Price Target to $62

Health Care

Management

Press Releases

DIH Announces Formation and Inaugural Meeting of Scientific Advisory Board

DIH Appoints Dietmar Dold as Chief Operating Officer

DIH Announces Second Quarter 2025 Financial Results and Restates June 30, 2024 Form 10-Q

General

DIH Appoints Sheltering Arms Institute as a DIH Center of Excellence

DIH Appoints Shepherd Center as a DIH Center of Excellence

DIH Announces Strategic Partnership with Nobis Rehabilitation Partners

DIH Announces Pricing of $4.6 Million Public Offering

DIH Announces Closing of $4.6 Million Public Offering

DIH Expands Strategic Partnership with Zahrawi Group

DIH Announces Third Quarter 2025 Financial Results

DHAI

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Aethlon Medical

Autonomix Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Bluejay Diagnostics

Biomerica

BioSig Technologies

Co-Diagnostics

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

HeartSciences

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

NanoVibronix

NAYA Biosciences

NeuroMetrix

Nuwellis

PAVmed

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Technologies

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tenon Medical

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Venus Concept

Xylo Technologies Ltd. - American Depositary Shares

Comments

DIH Holding US

DIH Holding US (DHAI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO